|
|
 |
|
Viewing report
|
|
|
|
Eli Lilly & Co.: PharmaVitae Profile
Datamonitor, July 2010, Pages: 101
Introduction
This analysis examines the historical and forecast performance for Eli Lilly in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Eli Lilly's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
Strategic insight into the prospects for Eli Lilly over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
- Benchmark Eli Lilly's performance against key rivals in the prescription pharmaceutical sector
- Assess the commercial outlook for key new launch products Effient and Bydureon
- Evaluate Eli Lilly's ability to overcome the adverse impact of patent expiry for Zyprexa, Cymbalta and other key franchises over the period 2011-14
|
|
|
|
